

- [1] S. Gudkov, N. Shilyagina, V. Vodeneev, and A. Zvyagin, "Targeted Radionuclide Therapy of Human Tumors," *Int. J. Mol. Sci.*, vol. 17, no. 1, p. 33, Dec. 2015, doi: 10.3390/ijms17010033.
- [2] A. Yordanova *et al.*, "Theranostics in nuclear medicine practice," *OncoTargets Ther.*, vol. Volume 10, pp. 4821–4828, Oct. 2017, doi: 10.2147/OTT.S140671.
- [3] H. Sung *et al.*, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA. Cancer J. Clin.*, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
- [4] R. Eychenne, M. Chérel, F. Haddad, F. Guérard, and J.-F. Gustin, "Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The 'Hopeful Eight,'" *Pharmaceutics*, vol. 13, no. 6, p. 906, June 2021, doi: 10.3390/pharmaceutics13060906.
- [5] T. Ertay, "Radionuclide Labeled Blood Cells," *Nucl. Med. Semin.*, vol. 9, no. 1, pp. 65–75, Mar. 2023, doi: 10.4274/nts.galenos.2023.0009.
- [6] U. Elboğa and N. Alan Selçuk, "Radionuclide Treatment in Pain Palliation," *Nucl. Med. Semin.*, vol. 6, no. 3, pp. 423–435, Dec. 2020, doi: 10.4274/nts.galenos..0035.
- [7] R. Gallant, R. Y. McNall-Knapp, and O. Khan, "Remote arterial vasculitis as a possible complication of Phosphorus-32 Radiosynovectomy," *Radiol. Case Rep.*, vol. 14, no. 2, pp. 137–140, Feb. 2019, doi: 10.1016/j.radcr.2018.09.022.
- [8] D. Zhai *et al.*, "Design and evaluation of  $^{32}\text{P}$ -labeled hydroxyapatite nanoparticles for bone tumor therapy," *Drug Deliv.*, vol. 30, no. 1, p. 2168791, Dec. 2023, doi: 10.1080/10717544.2023.2168791.
- [9] M. Galiè *et al.*, "Theranostic Role of  $^{32}\text{P}$ -ATP as Radiopharmaceutical for the Induction of Massive Cell Death within Avascular Tumor Core," *Theranostics*, vol. 7, no. 18, pp. 4399–4409, 2017, doi: 10.7150/thno.21403.
- [10] *Manual for reactor produced radioisotopes*. Vienna: IAEA.
- [11] IAEA, *Alternative Radionuclide Production with a Cyclotron*. in IAEA Radioisotopes and Radiopharmaceuticals Reports, no. v. 4. Vienna: IAEA, 2021.
- [12] W. Y. Rahman *et al.*, "Efficient production and purification of  $^{32}\text{P}$  radioisotope from sulfur by dry distillation: A practical approach with high radiochemical purity," *Appl. Radiat. Isot.*, vol. 211, p. 111416, Sept. 2024, doi: 10.1016/j.apradiso.2024.111416.
- [13] K. V. Vimalnath *et al.*, "Practicality of Production of  $^{32}\text{P}$  by Direct Neutron Activation for Its Utilization in Bone Pain Palliation as  $\text{Na}_3 [^{32}\text{P}] \text{PO}_4$ ," *Cancer Biother. Radiopharm.*, vol. 28, no. 5, pp. 423–428, June 2013, doi: 10.1089/cbr.2012.1335.
- [14] F. Y. Prastha, Z. Su'ud, and I. Kambali, "A novel dual-chamber cyclotron target for simultaneous production of F-18 and P-32," *Appl. Radiat. Isot.*, vol. 225, p. 112058, Nov. 2025, doi: 10.1016/j.apradiso.2025.112058.
- [15] M. Tatari, Z. Dehghan Manshadi, and H. Naik, "A theoretical study for the production of  $^{32}\text{P}$  radioisotope using neutrons from the  $^{68}\text{Zn}(p,n)^{68}\text{Ga}$  reaction in a medical cyclotron," *Appl. Radiat. Isot.*, vol. 188, p. 110347, Oct. 2022, doi: 10.1016/j.apradiso.2022.110347.
- [16] A. J. Koning, D. Rochman, J.-Ch. Sublet, N. Dzysiuk, M. Fleming, and S. Van Der Marck, "TENDL: Complete Nuclear Data Library for Innovative Nuclear Science and Technology," *Nucl. Data Sheets*, vol. 155, pp. 1–55, Jan. 2019, doi: 10.1016/j.nds.2019.01.002.
- [17] I. Kambali, I. R. Febrianto, R. Ritawidya, R. D. Haryuni, Marlina, and Nurhuda, "On the study of Cu-64 production from 18 MeV proton-induced secondary fast neutron bombardment," *J. Korean Phys. Soc.*, Dec. 2022, doi: 10.1007/s40042-022-00697-3.
- [18] I. Kambali *et al.*, "Development of Target Holder for the First Experiment on an Alternative Route for  $^{64}\text{Cu}$  Radioisotope Production by Secondary Neutron Irradiation of a  $^{64}\text{ZnO}$  Target," *Nucl. Sci. Eng.*, vol. 199, no. 5, pp. 829–837, May 2025, doi: 10.1080/00295639.2024.2392070.
- [19] K. Fajarwati, W. S. Budi, N. A. K. Umiati, and I. Kambali, "A novel method for Cu-64 radioisotope production by secondary neutrons irradiation of natural ZnO and enriched



- 64ZnO targets,” *Radiat. Phys. Chem.*, vol. 237, p. 113008, Dec. 2025, doi: 10.1016/j.radphyschem.2025.113008.
- [20] A. H. W. Lim *et al.*, “The Impact of Combined Chemotherapy and Intra-Tumoural Injection of Phosphorus-32 Microparticles on Vascularity in Locally Advanced Pancreatic Carcinoma,” *Cancers*, vol. 16, no. 19, 2024, doi: 10.3390/cancers16193412.
- [21] M. S. Bhutani *et al.*, “An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol,” *Endosc. Ultrasound*, vol. 9, no. 1, pp. 24–30, 2020, doi: 10.4103/eus.eus\_44\_19.
- [22] M. S. Bhutani *et al.*, “Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience,” *VideoGIE*, vol. 4, no. 5, pp. 223–225, 2019, doi: 10.1016/j.vgie.2019.02.009.
- [23] D. Chandra *et al.*, “32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect,” *Oncotarget*, vol. 8, no. 13, pp. 20729–20740, 2017, doi: 10.18632/oncotarget.15117.
- [24] Y. Cheng, A. P. Kiess, J. M. Herman, M. G. Pomper, S. J. Meltzer, and J. M. Abraham, “Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage,” *PLoS ONE*, vol. 10, no. 6, 2015, doi: 10.1371/journal.pone.0128152.
- [25] L. Sun, X. Zhu, L. Xu, Z. Wang, G. Shao, and J. Zhao, “Antitumor effects of 32P-chromic-poly (L-lactide) brachytherapy in nude mice with human prostate cancer,” *Oncol. Lett.*, vol. 6, no. 3, pp. 687–692, 2013, doi: 10.3892/ol.2013.1443.
- [26] C. Hu *et al.*, “Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma,” *Med. U. S.*, vol. 97, no. 26, 2018, doi: 10.1097/MD.00000000000011136.
- [27] H. Chang *et al.*, “Drug distribution and clinical safety in treating cystic craniopharyngiomas using intracavitary radiotherapy with phosphorus-32 colloid,” *Oncol. Lett.*, vol. 15, no. 4, pp. 4997–5003, 2018, doi: 10.3892/ol.2018.7981.
- [28] S. F. Ansari, R. J. Moore, J. C. Boaz, and D. H. Fulkerson, “Efficacy of phosphorus-32 brachytherapy without external-beam radiation for long-term tumor control in patients with craniopharyngioma,” *J. Neurosurg. Pediatr.*, vol. 17, no. 4, pp. 439–445, 2016, doi: 10.3171/2015.8.PEDS15317.
- [29] R. Zhao, J. Deng, X. Liang, J. Zeng, X. Chen, and J. Wang, “Treatment of cystic craniopharyngioma with phosphorus-32 intracavitary irradiation,” *Childs Nerv. Syst.*, vol. 26, no. 5, pp. 669–674, 2010, doi: 10.1007/s00381-009-1025-1.
- [30] X.-M. Wang, Z.-Y. Yin, R.-X. Yu, Y.-Y. Peng, P.-G. Liu, and G.-Y. Wu, “Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy,” *World J. Gastroenterol.*, vol. 14, no. 4, pp. 518–523, 2008, doi: 10.3748/wjg.14.518.
- [31] W. Assmann, R. Becker, C. Stief, and R. Sroka, “Development and pre-clinical test of a phosphorous-32 containing polyetheretherketone foil aiming at urethral stricture prevention by low-dose-rate brachytherapy,” *J. Contemp. Brachytherapy*, vol. 14, no. 2, pp. 189–197, 2022, doi: 10.5114/jcb.2022.115205.
- [32] R. X. Ma and Z. Li, “Therapeutic mechanism of 32P application combined with timolol maleate for infantile superficial hemangioma,” *Int. J. Radiat. Res.*, vol. 20, no. 1, pp. 157–162, 2022, doi: 10.52547/ijrr.20.1.24.
- [33] J. Zhang, Y. Li, G. Wen, Y. Deng, and H. Yao, “Novel Application of 32P Brachytherapy: Treatment of Angiolymphoid Hyperplasia with Eosinophilia in the Right Auricle with 8-Year Follow-Up,” *Cancer Biother. Radiopharm.*, vol. 33, no. 7, pp. 282–284, 2018, doi: 10.1089/cbr.2018.2468.
- [34] H. Vivante, M. Salgueiro, R. Ughetti, J. Nicolini, and M. Zubillaga, “32P-patch contact brachyradiotherapy in the management of recalcitrant keloids and hypertrophic scars,” *Indian J. Dermatol. Venereol. Leprol.*, vol. 73, no. 5, pp. 336–339, 2007, doi: 10.4103/0378-6323.35736.



- [35] A. Dash and T. Das, "Production of therapeutic radionuclides for bone-seeking radiopharmaceuticals to meet clinical exigency and academic research," *J. Radioanal. Nucl. Chem.*, vol. 334, no. 4, pp. 2591–2611, 2025, doi: 10.1007/s10967-025-10025-1.
- [36] D. Handkiewicz-Junak *et al.*, "EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 45, no. 5, pp. 846–859, 2018, doi: 10.1007/s00259-018-3947-x.
- [37] F. D. C. Guerra Liberal, A. A. S. Tavares, and J. M. R. S. Tavares, "Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods," *Med. Phys.*, vol. 41, no. 11, 2014, doi: 10.1118/1.4897240.
- [38] E. L. Vernon, T. P. Bean, and A. N. Jha, "Assessing relative biomarker responses in marine and freshwater bivalve molluscs following exposure to phosphorus 32 (32P): Application of genotoxicological and molecular biomarkers," *J. Environ. Radioact.*, vol. 213, 2020, doi: 10.1016/j.jenvrad.2019.106120.
- [39] K. M. Parker, V. Barragán Borrero, D. M. Van Leeuwen, M. A. Lever, B. Mateescu, and M. Sander, "Environmental Fate of RNA Interference Pesticides: Adsorption and Degradation of Double-Stranded RNA Molecules in Agricultural Soils," *Environ. Sci. Technol.*, vol. 53, no. 6, pp. 3027–3036, 2019, doi: 10.1021/acs.est.8b05576.
- [40] E. L. Vernon, J. T. Smith, and A. N. Jha, "Relative comparison of tissue specific bioaccumulation and radiation dose estimation in marine and freshwater bivalve molluscs following exposure to phosphorus-32," *J. Environ. Radioact.*, vol. 192, pp. 312–320, 2018, doi: 10.1016/j.jenvrad.2018.07.005.
- [41] J. T. Smith, M. J. Bowes, and C. R. Cailes, "A review and model assessment of 32P and 33P uptake to biota in freshwater systems," *J. Environ. Radioact.*, vol. 102, no. 4, pp. 317–325, 2011, doi: 10.1016/j.jenvrad.2010.12.006.
- [42] A. N. H. Creager, "Phosphorus-32 in the Phage Group: radioisotopes as historical tracers of molecular biology," *Stud. Hist. Philos. Sci. Part C Stud. Hist. Philos. Biol. Biomed. Sci.*, vol. 40, no. 1, pp. 29–42, Mar. 2009, doi: 10.1016/j.shpsc.2008.12.005.
- [43] Y. Cheng, A. P. Kiess, J. M. Herman, M. G. Pomper, S. J. Meltzer, and J. M. Abraham, "Phosphorus-32, a Clinically Available Drug, Inhibits Cancer Growth by Inducing DNA Double-Strand Breakage," *PLOS ONE*, vol. 10, no. 6, p. e0128152, June 2015, doi: 10.1371/journal.pone.0128152.
- [44] A. Rizaludin *et al.*, "Phosphorus-32 labelled irradiated bovine hydroxyapatite for radiosynovectomy," *J. Radioanal. Nucl. Chem.*, vol. 334, no. 2, pp. 1195–1204, Feb. 2025, doi: 10.1007/s10967-024-09917-5.
- [45] D. Yan, B. Zhao, H. Yang, B. Zhu, and J. Wang, "A combination of nonoperative treatment modalities used for treatment of keloids: A combination approach to therapy of keloids," *Dermatol. Ther.*, vol. 27, no. 1, pp. 48–51, Jan. 2014, doi: 10.1111/dth.12044.
- [46] E. E. Limmer and D. A. Glass, "A Review of Current Keloid Management: Mainstay Monotherapies and Emerging Approaches," *Dermatol. Ther.*, vol. 10, no. 5, pp. 931–948, Oct. 2020, doi: 10.1007/s13555-020-00427-2.
- [47] L. Xie, L. Huang, G. Zhang, and Y. Su, "Inhibition of keloid by 32P isotope radiotherapy through suppressing TGF- $\beta$ /Smad signaling pathway," *Aging*, vol. 15, no. 21, pp. 11985–11993, Nov. 2023, doi: 10.18632/aging.205160.
- [48] M. J. Salgueiro *et al.*, "Biological effects of brachytherapy using a 32P-patch on the skin of Sencar mice," *Appl. Radiat. Isot.*, vol. 67, no. 10, pp. 1769–1774, Oct. 2009, doi: 10.1016/j.apradiso.2009.05.006.
- [49] M. Salgueiro, R. Ughetti, J. Nicolini, M. Zubillaga, and H. Vivante, "<sup>32</sup>P-patch contact brachyradiotherapy in the management of recalcitrant keloids and hypertrophic scars," *Indian J. Dermatol. Venereol. Leprol.*, vol. 73, no. 5, p. 336, 2007, doi: 10.4103/0378-6323.35736.
- [50] A. Pashazadeh, H. R. Baghani, M. Robatjazi, and P. Kadavil, "The effect of geometrical parameters of skin brachytherapy patch source on depth dose distribution using Monte Carlo simulation," *Appl. Radiat. Isot.*, vol. 204, p. 111117, Feb. 2024, doi: 10.1016/j.apradiso.2023.111117.



- [51] M. J. Salgueiro *et al.*, "Radioactive treatment of a murine melanoma using a  $^{32}\text{P}$ -patch," *Nucl. Med. Commun.*, vol. 30, no. 9, pp. 706–712, Sept. 2009, doi: 10.1097/MNM.0b013e32832b9aad.
- [52] C. Parmentier, "Use and risks of phosphorus-32 in the treatment of polycythaemia vera," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 30, no. 10, pp. 1413–1417, Oct. 2003, doi: 10.1007/s00259-003-1270-6.
- [53] N. I. Berlin, "Treatment of the myeloproliferative disorders with  $^{32}\text{P}$ ," *Eur. J. Haematol.*, vol. 65, no. 1, pp. 1–7, July 2000, doi: 10.1034/j.1600-0609.2000.9r119.x.
- [54] X. Yu *et al.*, "Evaluation of Long-Term Outcomes and Toxicity After Stereotactic Phosphorus-32–Based Intracavitary Brachytherapy in Patients With Cystic Craniopharyngioma," *Int. J. Radiat. Oncol.*, vol. 111, no. 3, pp. 773–784, Nov. 2021, doi: 10.1016/j.ijrobp.2021.05.123.
- [55] M. Babaei, R. Ghahramani-Asl, H.-R. Sadoughi, D. Sardari, and S. Shahzadi, "Evaluation of Bremsstrahlung radiation dose in stereotactically radiocolloid therapy of cystic craniopharyngioma tumors with  $^{32}\text{P}$  radio-colloid," *Australas. Phys. Eng. Sci. Med.*, vol. 41, no. 3, pp. 697–711, Sept. 2018, doi: 10.1007/s13246-018-0665-4.
- [56] Ye. A. Karelin *et al.*, "Radionuclide production using a fast flux reactor," *Appl. Radiat. Isot.*, vol. 53, no. 4–5, pp. 825–827, Nov. 2000, doi: 10.1016/s0969-8043(00)00236-0.
- [57] J. Alanís and M. Navarrete, "Industrial production and purification of  $^{32}\text{P}$  by sulfur irradiation with partially moderated neutron fluxes and target melting," *J. Radioanal. Nucl. Chem.*, vol. 273, no. 3, pp. 659–662, Sept. 2007, doi: 10.1007/s10967-007-0927-1.
- [58] K. V. Vimalnath *et al.*, "Practicality of Production of  $^{32}\text{P}$  by Direct Neutron Activation for Its Utilization in Bone Pain Palliation as  $\text{Na}_3[^{32}\text{P}]\text{PO}_4$ ," *Cancer Biother. Radiopharm.*, vol. 28, no. 5, pp. 423–428, June 2013, doi: 10.1089/cbr.2012.1335.
- [59] K. V. Vimalnath, P. Shetty, A. Rajeswari, V. Chirayil, S. Chakraborty, and A. Dash, "Reactor production of  $^{32}\text{P}$  for medical applications: an assessment of  $^{32}\text{S}(\text{n},\text{p})^{32}\text{P}$  and  $^{31}\text{P}(\text{n},\gamma)^{32}\text{P}$  methods," *J. Radioanal. Nucl. Chem.*, vol. 301, no. 2, pp. 555–565, Aug. 2014, doi: 10.1007/s10967-014-3115-0.
- [60] I. Kambali and I. R. Febrianto, "Feasibility Study of Copper-64 Radioisotope Production by Secondary Fast Neutron Bombardment," *IOP Conf. Ser. Earth Environ. Sci.*, vol. 927, no. 1, p. 012034, Dec. 2021, doi: 10.1088/1755-1315/927/1/012034.
- [61] I. Kambali, I. R. Febrianto, R. Ritawidya, R. D. Haryuni, Marlina, and Nurhuda, "On the study of Cu-64 production from 18 MeV proton-induced secondary fast neutron bombardment," *J. Korean Phys. Soc.*, Dec. 2022, doi: 10.1007/s40042-022-00697-3.
- [62] L. Auditore, E. Amato, and S. Baldari, "Theoretical estimation of  $^{64}\text{Cu}$  production with neutrons emitted during  $^{18}\text{F}$  production with a 30 MeV medical cyclotron," *Appl. Radiat. Isot.*, vol. 122, pp. 229–234, Apr. 2017, doi: 10.1016/j.apradiso.2017.02.002.
- [63] D. Alloni and M. Prata, "Characterisation of the secondary neutron field generated by a compact PET cyclotron with MCNP6 and experimental measurements," *Appl. Radiat. Isot.*, vol. 128, pp. 204–209, Oct. 2017, doi: 10.1016/j.apradiso.2017.07.031.
- [64] M. Tatari, Z. Dehghan Manshadi, and H. Naik, "A theoretical study for the production of  $^{32}\text{P}$  radioisotope using neutrons from the  $^{68}\text{Zn}(\text{p},\text{n})^{68}\text{Ga}$  reaction in a medical cyclotron," *Appl. Radiat. Isot.*, vol. 188, p. 110347, Oct. 2022, doi: 10.1016/j.apradiso.2022.110347.
- [65] J. F. Ziegler, M. D. Ziegler, and J. P. Biersack, "SRIM – The stopping and range of ions in matter (2010)," *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.*, vol. 268, no. 11–12, pp. 1818–1823, June 2010, doi: 10.1016/j.nimb.2010.02.091.
- [66] A. Hermanne, R. Adam-Rebeles, P. Van Den Winkel, F. Tárkányi, and S. Takács, "Production of  $^{111}\text{In}$  and  $^{114\text{m}}\text{In}$  by proton induced reactions: an update on excitation functions, chemical separation – purification and recovery of target material," *Radiochim. Acta*, vol. 102, no. 12, pp. 1111–1126, Dec. 2014, doi: 10.1515/ract-2013-2233.
- [67] M. U. Khandaker, H. Haba, M. Murakami, and N. Otuka, "Production cross-sections of long-lived radionuclides in deuteron-induced reactions on natural zinc up to 23 MeV," *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.*, vol. 346, pp. 8–16, Mar. 2015, doi: 10.1016/j.nimb.2015.01.011.





- [68] M. Yigit and E. Tel, "Nuclear model calculation for production of  $^{18}\text{F}$ ,  $^{22}\text{Na}$ ,  $^{44}\text{Sc}$ ,  $^{54}\text{Mn}$ ,  $^{64}\text{Cu}$ ,  $^{68}\text{Ga}$ ,  $^{76}\text{Br}$  and  $^{90}\text{Y}$  radionuclides used in medical applications," *Ann. Nucl. Energy*, vol. 69, pp. 44–50, July 2014, doi: 10.1016/j.anucene.2014.01.036.
- [69] M. Sadeghi, M. Enferadi, and M. Bakhtiari, "Accelerator production of the positron emitter zirconium-89," *Ann. Nucl. Energy*, vol. 41, pp. 97–103, Mar. 2012, doi: 10.1016/j.anucene.2011.11.014.
- [70] G. F. Steyn *et al.*, "Cross sections of proton-induced reactions on  $^{152}\text{Gd}$ ,  $^{155}\text{Gd}$  and  $^{159}\text{Tb}$  with emphasis on the production of selected Tb radionuclides," *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.*, vol. 319, pp. 128–140, Jan. 2014, doi: 10.1016/j.nimb.2013.11.013.
- [71] B. Liu *et al.*, "Excitation functions of proton induced reactions on titanium and copper," *Appl. Radiat. Isot.*, vol. 173, p. 109713, July 2021, doi: 10.1016/j.apradiso.2021.109713.
- [72] K. I. Zolotarev, "RE-EVALUATION OF MICROSCOPIC AND INTEGRAL CROSS-SECTION DATA FOR IMPORTANT DOSIMETRY REACTIONS," 2008.
- [73] B. M. Saied and N. F. Naji, "YIELDS FOR THE PRODUCTION OF PHOSPHORUS-32 USING THE CHARGED AND UNCHARGED PARTICLES IN MEDICAL PRACTICE".

